Drug intelligence / Profile preview

M-Vax

Development stage: Phase 3
Lead developer: AVAX Technologies
Modality: Vaccines & Immunotherapeutics
Administration: Intradermal

Overview

**M-Vax** is an individualized therapeutic cancer vaccine developed by AVAX Technologies for melanoma. It consists of a patient's own melanoma cells that are irradiated, chemically haptenized with dinitrophenyl, and administered by intradermal injection with Bacille Calmette-Guérin as an immunologic adjuvant. Haptenization is intended to increase immune recognition of autologous tumor antigens and induce tumor-reactive cellular immunity, including delayed-type hypersensitivity responses and infiltration of melanoma metastases by activated T cells. M-Vax was studied in stage III and stage IV melanoma, including registered phase I/II and phase III trials; its present overall development and commercial status could not be confirmed from current public trial records. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/11890872/))

Brand names: M-Vax
Other names: DNP-VACC

Targets

DNP (Dinitrophenyl)

Beyond the preview

Go deeper on M-Vax.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on M-Vax.

Explore the full profile